Zenas BioPharma (ZBIO) Operating Leases (2023 - 2026)

Zenas BioPharma's Operating Leases history runs 4 years deep, the most recent figure standing at $77000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 75.71% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at $77000.0 (down 75.71% YoY), while the FY2025 annual figure was $211000.0, down 3.21% from the prior year.
• Operating Leases was $77000.0 for Q1 2026 at Zenas BioPharma, down from $211000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $317000.0 in Q1 2025 to a low of $77000.0 in Q1 2026.
• Historically, Operating Leases has averaged $210714.3 across 4 years, with a median of $215000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Operating Leases retreated 3.21% in 2025, then sank 75.71% in 2026.
• A 4-year view of Operating Leases shows it stood at $257000.0 in 2023, then fell by 15.18% to $218000.0 in 2024, then decreased by 3.21% to $211000.0 in 2025, then slumped by 63.51% to $77000.0 in 2026.
• The last three Operating Leases figures came in at $77000.0 (Q1 2026), $211000.0 (Q4 2025), and $180000.0 (Q3 2025), per Business Quant data.